Diglycosylated erythropoietin
US6930086B2 · kind B2 · utility
8Cited by
0References
44Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Sep 11, 2002 |
| Grant date | Aug 16, 2005 |
| Priority date | — |
| Expiry date | Dec 2, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention is directed to an erythropoietin mutein having in vivo biological activity for causing bone marrow cells to increase production of reticulocytes and red blood cells, in that the mutein is N-glycosylated at Asn38 and Asn83 but not N-glycosylated at Asn24. Such muteins have improved pharmaceutical properties.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.